Skip to content
- Eli Lilly’s Tirzepatide Reduces Heart Failure Risk, Company SaysNBC News
- Eli Lilly’s Diet Drug Zepbound Lowers Heart Failure Risk in Late-Stage StudyCNBC
- Eli Lilly says tirzepatide showed positive results in a late-stage study evaluating it as a treatment for heart failureMarket overview
- Pharmalittle: We look at positive Zepbound cardiovascular data, a move to take 23andMe private, and moreSTANDS
- Lilly’s Tirzepatide Successful in Phase 3 Study Shows Benefit in Adults with Heart Failure with Preserved Ejection Fraction and ObesityInvestors | Eli Lilly and Company
